Short answer
Kura Oncology, Inc. (KURA) filed an 8-K current report with the SEC on March 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 financial results announced March 5, 2026: full figures in Exhibit 99.1.
Kura Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results announced March 5, 2026: full figures in Exhibit 99.1
- KURA is a clinical-stage oncology company; results likely reflect R&D spend, cash runway, and pipeline progress rather than product revenue
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kura Oncology, Inc. 8-K filings
Get the next KURA 8-K as it lands
Follow KURA for push alerts, or ask the research agent what this filing means.